The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 23, 2010

Filed:

Nov. 22, 2004
Applicants:

Christopher Penney, Pierrefonds, CA;

Boulos Zacharie, Laval, CA;

Shaun D. Abbott, Pointe-Claire, CA;

Jean-françois Bienvenu, Laval, CA;

Alan D. Cameron, Montreal, CA;

Jean-simon Duceppe, St.-Colomban, CA;

Abdallah Ezzitouni, Laval, CA;

Daniel Fortin, Rosemère, CA;

Karine Houde, Montreal, CA;

Nancie Moreau, Laval, CA;

Nicole Wilb, Montreal, CA;

Brigitte Grouix, Montreal, CA;

Lyne Gagnon, Laval, CA;

Inventors:

Christopher Penney, Pierrefonds, CA;

Boulos Zacharie, Laval, CA;

Shaun D. Abbott, Pointe-Claire, CA;

Jean-François Bienvenu, Laval, CA;

Alan D. Cameron, Montreal, CA;

Jean-Simon Duceppe, St.-Colomban, CA;

Abdallah Ezzitouni, Laval, CA;

Daniel Fortin, Rosemère, CA;

Karine Houde, Montreal, CA;

Nancie Moreau, Laval, CA;

Nicole Wilb, Montreal, CA;

Brigitte Grouix, Montreal, CA;

Lyne Gagnon, Laval, CA;

Assignee:

ProMetic BioSciences Inc., Montreal, Quebec, CA;

Attorney:
Int. Cl.
CPC ...
C07D 403/12 (2006.01); C07D 403/14 (2006.01); A61K 31/53 (2006.01); A61K 39/395 (2006.01); A61P 13/12 (2006.01); A61P 17/06 (2006.01); A61P 19/02 (2006.01); A61P 37/00 (2006.01); A61M 1/36 (2006.01); C07K 1/22 (2006.01); C07K 16/24 (2006.01);
U.S. Cl.
CPC ...
Abstract

Compounds containing two mono- or disubstituted triazine rings covalently linked by an organic linker, but not linked directly to each other, may be used to treat autoimmune diseases. Autoimmune diseases which are amenable to treatment with compounds of this invention include rheumatoid arthritis, systemic lupus erythematosus (SLE), idiopathic (immune) thrombocytopenia (ITP), glomerulonephritis and vasculitis. The present invention also relates to reducing drug toxicity which often accompanies traditional therapies for autoimmune diseases. The compounds may also be used to bind antibody in vitro or ex vivo.


Find Patent Forward Citations

Loading…